The public spotlight has turned toward monoclonal antibody therapies for COVID-19 following President Trump’s recent treatment with Regeneron Pharmaceuticals, Inc.’s experimental cocktail and Eli Lilly and Company’s move to seek an emergency use authorization for its single antibody drug, raising questions about how they will be priced.
Regeneron’s manufacturing and supply agreement with the US government for its antibody treatment offers some preliminary guidance. Under the Regeneron contract, the government has committed $450m to support manufacturing of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?